DBV Technologies S.A. (DBVT) Trading Up 11%
DBV Technologies S.A. (NASDAQ:DBVT) was up 11% during mid-day trading on Monday . The company traded as high as $26.08 and last traded at $26.00. Approximately 1,158,802 shares were traded during mid-day trading, an increase of 416% from the average daily volume of 224,461 shares. The stock had previously closed at $23.43.
A number of equities research analysts have recently issued reports on DBVT shares. BidaskClub upgraded shares of DBV Technologies from a “hold” rating to a “buy” rating in a research note on Tuesday, July 25th. Zacks Investment Research upgraded shares of DBV Technologies from a “sell” rating to a “hold” rating and set a $49.00 target price on the stock in a research note on Tuesday, August 1st. Leerink Swann upped their target price on shares of DBV Technologies from $54.00 to $60.00 and gave the company an “outperform” rating in a research note on Friday, August 25th. Finally, Jefferies Group LLC restated a “buy” rating on shares of DBV Technologies in a research note on Thursday, August 31st. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and nine have given a buy rating to the company’s stock. DBV Technologies currently has an average rating of “Buy” and a consensus price target of $49.63.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in DBVT. Janus Henderson Group PLC acquired a new stake in DBV Technologies during the second quarter worth about $90,724,000. Jennison Associates LLC raised its stake in DBV Technologies by 86.4% during the second quarter. Jennison Associates LLC now owns 1,002,067 shares of the company’s stock worth $35,784,000 after acquiring an additional 464,341 shares during the period. Citadel Advisors LLC bought a new position in DBV Technologies in the 3rd quarter worth about $7,794,000. Morgan Stanley grew its position in DBV Technologies by 89.9% in the 1st quarter. Morgan Stanley now owns 249,988 shares of the company’s stock worth $8,805,000 after purchasing an additional 118,317 shares during the last quarter. Finally, Botty Investors LLC bought a new position in DBV Technologies in the 2nd quarter worth about $2,231,000. Hedge funds and other institutional investors own 44.71% of the company’s stock.
About DBV Technologies
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.
Receive News & Stock Ratings for DBV Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies S.A. and related stocks with our FREE daily email newsletter.